Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2016

View Archived Issues

Light-activated quantum dots show promise as phototherapy for multidrug-resistant infections

Oxeia Biopharmaceuticals develops OXE-103 for concussion

Lysyl oxidase identified as a factor in thrombosis risk

FDA approves Botox for the treatment of lower limb spasticity in adults

FDA clears IND application for Agenus' anti-CTLA-4 and anti-GITR antibodies

GSK discontinues development of alitretinoin in U.S.

Phase II results indicate sustained expression with AAT deficiency gene therapy

FDA grants orphan drug designation to TRACON's anti-endoglin antibody

Broad Institute Genomic Services and Takeda partner to expand genomic insight into Ninlaro

Genentech and Xenon Pharmaceuticals patent Nav1.7 channel blockers

Immunocore's IMCgp-100 gets FDA orphan drug designation for uveal melanoma

Incyte discloses KDM1A inhibitors

ST Pharm presents tankyrase-1 inhibitors

Pharmacyclics reports BTK inhibitors

Takeda's H. influenzae type b conjugate vaccine approved in Japan

Bonviva tablet approved in Japan for the treatment of osteoporosis

bioTheranostics to spin out from bioMerieux

Apollo Therapeutics Fund established to advance preclinical drug R&D at U.K. universities

Expanded FDA approvals for Opdivo + Yervoy and single-agent Opdivo in melanoma

Shire's acquisition of Dyax complete

Merck & Co. studies [11C]MK-6884 as PET imaging agent

FDA grants orphan drug designation to mutant KIT inhibitor for mastocytosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...